Matthias A Karajannis
Overview
Explore the profile of Matthias A Karajannis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
6472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonm A, Rutenberg M, Therkelsen K, Herbst J, Sanaf A, Sherwood M, et al.
Neurooncol Adv
. 2025 Feb;
7(1):vdae231.
PMID: 39991182
Background: Adult onset medulloblastoma (aMB) is a rare tumor with limited available evidence. We present a large multi-institutional retrospective cohort of aMB patients treated in the modern era, with an...
2.
Karajannis M, Onar-Thomas A, Lin T, Baxter P, Boue D, Cole B, et al.
Neuro Oncol
. 2024 Nov;
PMID: 39560182
Background: The outcome for pediatric patients with high-grade glioma (HGG) remains poor. Veliparib, a potent oral poly(adenosine diphosphate-ribose) polymerase (PARP) 1/2 inhibitor, enhances the activity of radiotherapy and DNA-damaging chemotherapy....
3.
Logan I, Nguyen K, Chatterjee T, Manivannan B, Paul N, Kim S, et al.
Redox Biol
. 2024 Jun;
75:103249.
PMID: 38945076
Tumors develop in an oxidative environment characterized by peroxynitrite production and downstream protein tyrosine (Y) nitration. We showed that tyrosine nitration supports schwannoma cell proliferation and regulates cell metabolism in...
4.
Mankuzhy N, Tringale K, Dunkel I, Farouk Sait S, Souweidane M, Khakoo Y, et al.
Pediatr Blood Cancer
. 2024 Mar;
71(5):e30929.
PMID: 38430472
Background: Re-irradiation (reRT) increases survival in locally recurrent diffuse intrinsic pontine glioma (DIPG). There is no standard dose and fractionation for reRT, but conventional fractionation (CF) is typically used. We...
5.
Hardin H, Dinh C, Huegel J, Petrilli A, Bracho O, Allaf A, et al.
Mol Cancer Ther
. 2023 Aug;
22(11):1280-1289.
PMID: 37527526
Neurofibromatosis Type 2 (NF2) is a tumor predisposition syndrome caused by germline inactivating mutations in the NF2 gene encoding the merlin tumor suppressor. Patients develop multiple benign tumor types in...
6.
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, et al.
Neurooncol Adv
. 2023 Jul;
5(1):vdad076.
PMID: 37476329
Background: Central nervous system (CNS) cancer is the 10th leading cause of cancer-associated deaths for adults, but the leading cause in pediatric patients and young adults. The variety and complexity...
7.
Benhamida J, Harmsen H, Ma D, William C, Li B, Villafania L, et al.
Brain Pathol
. 2023 Jul;
33(5):e13185.
PMID: 37399073
Fusions involving CRAF (RAF1) are infrequent oncogenic drivers in pediatric low-grade gliomas, rarely identified in tumors bearing features of pilocytic astrocytoma, and involving a limited number of known fusion partners....
8.
Kolodziejczak A, Guerrini-Rousseau L, Planchon J, Ecker J, Selt F, Mynarek M, et al.
Neuro Oncol
. 2023 Jun;
25(12):2273-2286.
PMID: 37379234
Background: The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here,...
9.
Diaz M, Rana S, Silva Correia C, Reiner A, Lin A, Miller A, et al.
Neurooncol Adv
. 2023 Jun;
5(1):vdad068.
PMID: 37346983
Background: The 2016 WHO classification described a subtype of midline gliomas harboring histone 3 (H3) K27M alterations, and the 2021 edition added a new subtype of hemispheric diffuse gliomas with...
10.
Farouk Sait S, Fischer C, Antal Z, Spatz K, Prince D, Ibanez K, et al.
Pediatr Blood Cancer
. 2023 May;
:e30410.
PMID: 37158537
Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long-term safety data are limited, and serious toxicities unique to pediatrics may emerge....